Alkali metal doped crystalline g-C3N4 with an enriched cyano group for visible-light photocatalytic degradation of methylamine.

In this study, alkali-metal-doped crystalline g-C3N4 with an enriched cyano group was synthesized using the molten salt method and used for the visible-light photocatalytic degradation of methylamine (MA), a common organic amine compound with a low odor threshold. Different types and proportions of melting salts (Li, K, and Na) were added during secondary calcination to regulate the morphology, crystallinity, and surface defects of graphitic carbon nitride (g-C3N4). With molten salt treatment matched the melting point of the binary salt system, a cyano group and alkali metal co-doped crystalline g-C3N4 with a high surface area and good crystallinity were prepared. Co-decorating the alkali metal and cyano groups on crystalline g-C3N4 facilitated the adsorption of MA, realized an excellent photo-charge transfer efficiency, and generated more superoxide radicals. Compared with pristine g-C3N4 (PCN), the apparent rate constant of LiK15 : 5-CCN for the degradation of MA increased by 10.2 times and the degradation efficiency of 1000 ppm MA gas was 93.1% after 90 min of irradiation with visible light, whereas the degradation efficiency of PCN was 19.2%.

The combination treatment strategy of lenvatinib for hepatocellular carcinoma: a real-world study.

PURPOSE: Lenvatinib is recommended as a first-line therapy in unresectable hepatocellular carcinoma (HCC). Combination therapy with local therapy (LT) or PD-1/PD-L1 inhibitors (PI) might improve the antitumor effect of lenvatinib. The objective of this study was to investigate the antitumor effect of lenvatinib-based combination therapies. METHODS: The study retrospectively analyzed 215 HCC patients who received lenvatinib therapy. The outcomes of patients treated with lenvatinib monotherapy as well as combination strategies were compared. Progression-free survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was the primary endpoint, while PFS by mRECIST, overall survival (OS), objective response rate (ORR) and safety were the secondary endpoints. Propensity score matching (PSM) analysis was performed to overcome the bias of baseline characteristics. RESULTS: Compared with lenvatinib monotherapy, combination therapy prolonged PFS (by RECIST v1.1, 7.77 vs. 4.43 months, P = 0.045; by mRECIST, 6.97 vs. 5.27 months, P = 0.067). A higher ORR was also recorded in the combined-therapy group, according to both RECIST v1.1 (37 vs. 5%, P < 0.001) and mRECIST (53 vs. 11%, P < 0.001). Similar outcomes were obtained after PSM. Moreover, triple therapy (combined with both PI and LT) was significantly superior to dual therapy (combined with either PI or LT) in terms of better PFS according to RECIST v1.1 (8.90 vs. 6.43 months, P = 0.023). However, adverse events occurred in more patients receiving combined therapy and triple therapy. No difference was observed in OS between groups. CONCLUSION: Combination therapies based on lenvatinib were associated with significantly better PFS and tumor response rates than lenvatinib monotherapy in HCC patients.

Boosted CO2 photoreduction performance on Ru-Ti3CN MXene-TiO2 photocatalyst synthesized by non-HF Lewis acidic etching method.

Photocatalytic CO2 reduction to produce value-added products is considered a promising solution to solve the global energy crisis and the greenhouse effect. In this study, Ti3CN MXene was synthesized using a Lewis acidic etching method without the usage of toxic hydrofluoric acid (HF). Ti3CN MXene was then used as a support for the in situ hydrothermal growth of TiO2 and Ru nanoparticles. In the presence of 0.5 wt% Ru, Ru-Ti3CN-TiO2 shows CO and CH4 production rates of 99.58 and 8.97 µmol/g, respectively, in 5 h under Xenon lamp irradiation, more than 20.5 and 9.3 times that of commercial P25. The enhancement in photocatalytic activity was attributed to the synergy between the in-situ growth of TiO2 on Ti3CN MXene and Ru nanoparticles. It was proven experimentally that Ti3CN MXene can provide abundant pathways for electron transfer. The separation and transfer of the photo-induced charge were further increased with the help of Ru and Ti3CN MXene, leaving more electrons to participate in the subsequent CO2 reduction reaction. We believe that this work will encourage more attention to designing environment-friendly MXene-based photocatalysts for CO2 photoreduction using the non-HF method.

Comparison of stereotactic body radiation therapy with hepatic resection and radiofrequency ablation as initial treatment in patients with early-stage hepatocellular carcinoma.

Background: Stereotactic body radiation therapy (SBRT) has emerged as a novel intervention for early-stage hepatocellular carcinoma (HCC). The outcomes of SBRT, liver resection (LR), and radiofrequency ablation (RFA) as the initial treatment for AJCC stage I HCC patients remain unclear. Methods: Patients with AJCC stage I HCC from the Surveillance, Epidemiology and End Results database were analyzed for survival rates using the Kaplan-Meier method and stratified according to tumor size: S subgroup (≤2 cm), M subgroup (>2-3 cm), and L subgroup (>3 cm). For factors including age, year of diagnosis, sex, race, grade, tumor size, AFP, and fibrosis score, propensity score matching was performed to eliminate the imbalance of baseline features and selection bias during groups. Results: A total of 4,002 patients were included; the difference in median overall survival (mOS) between the SBRT group and the LR or RFA group in the S subgroup was statistically insignificant (p=0.109 and p=0.744), while that of the RFA group was significantly worse than that of the LR group (p <0.001). In the M and L subgroups, the mOS of the SBRT group was worse than that of the RFA group (p=0.040 and p<0.001, respectively). The mOS of LR was the best when compared with either the SBRT or RFA group regardless of the subgroup M or L (all p<0.001). Conclusion: For HCC ≤ 2 cm, SBRT can be used as an alternative treatment for RFA. For patients with HCC larger than 2 cm, RFA can provide better long-term survival than SBRT, while LR remains the best choice.

Optimal subsequent treatments for patients with hepatocellular carcinoma resistant to anti-PD-1 treatment.

Aim: The subsequent treatments for patients with hepatocellular carcinoma (HCC) resistant to immunotherapy remain unclear. This study aimed to identify optimal treatments for HCC patients with progression after anti-PD-1 therapy. Methods: The authors retrospectively analyzed 197 HCC patients with progressive disease after anti-PD-1 treatment. These patients were classified into initial resistant and secondary resistant groups. Results: In the initial resistant group, subsequent treatment with PD-1 antibody plus locoregional therapy prolonged post-progression survival and overall survival (p = 0.025 and 0.029, respectively). In the secondary resistant group, subsequent treatment did not improve the prognosis of patients. Conclusion: Subsequent PD-1 antibody plus locoregional therapy could achieve survival benefits in HCC patients initially resistant to anti-PD-1 immunotherapy.

Lay abstract This study explored the optimal subsequent treatments for patients with hepatocellular carcinoma resistant to anti-PD-1 therapy. Patients were classified into initial resistant and secondary resistant groups according to whether they had responses to previous anti-PD-1 immunotherapy. By evaluating the prognosis of different treatment modalities in the initial and secondary resistant groups, the authors found that subsequent PD-1 antibody plus locoregional therapy provided survival benefits for patients with hepatocellular carcinoma initially resistant to anti-PD-1 immunotherapy. As for patients with secondary resistance, the optimal subsequent treatments need to be further explored.